



800-540-7252

To Our Physician Partners,

We are writing you regarding the recent recall from Philips Respironics that affects equipment your patient received from us. This recall is for Philips Respironics CPAP, BiPAP, BiPAP ST and Trilogy 100/200 ventilators.

This recall affects Medi-Rents & Sales, Inc. as well as all DME companies nationwide and will have implications on the manufacturing and shipment of CPAP, BiPAP and home ventilators for the foreseeable future. We at Medi-Rents & Sales Inc. will be in communication with you as solutions become available. At this time, we do not have the inventory available nor is it available from other manufacturers to switch your equipment out at this time. Philips Respironics is working on a solution to replace the equipment but the time frame is unknown. Please see the enclosed recall notices and recommended actions. Please discuss next steps with your patient based off of these recommendations. Further information is also available at www.usa.philips.com/healthcare/e/sleep/communications/src-update
Philips Respironics Phone # 877-907-7508

If you and your patient decide that the benefits outweigh the risks of the recall, please complete the next page and fax back to us.

Thank you for your patience and understanding as we work together during these unprecedented times.

Sincerely,

Christopher Petr

COO

BiPAP ST & TRILOGY 100 & 200

Philips Respironics Respiratory Equipment Continued Use After Recall

I (*physician name*) _____ have received notification of the Philips Respironics recall and understand at this time that a replacement device is not available. I have discussed the recall with my (*patient name*) _____ and have concluded that the benefits of continued use of the Respironics BiPAP ST or Trilogy Ventilator outweighs the risks of not using it. I will not hold Medi-Rents & Sales, Inc. liable for mine and my patients decision for my patient to continue using the equipment after the manufacturer recall.

Physician Name

Signature

NPI

Date

FAX TO: 844-818-9293

or

EMAIL TO:

recall@medirents.net

URGENT: Medical Device Recall

Philips Respironics

Trilogy 100, Trilogy 200, Garbin Plus, Aeris, LifeVent, BiPAP V30, and BiPAP A30/A40 Series Device Models

Sound Abatement Foam Susceptibility to Degradation and Volatile Organic Compound Emission

Dear Device Customer,

Philips Respironics is voluntarily recalling the below devices due to two (2) issues related to the polyester-based polyurethane (PE-PUR) sound abatement foam used in Philips Continuous and Non-Continuous Ventilators: 1) PE-PUR foam may degrade into particles which may enter the device's air pathway and be ingested or inhaled by the user, and 2) the PE-PUR foam may off-gas certain chemicals. The foam degradation may be exacerbated by use of unapproved cleaning methods, such as ozone (see [FDA safety communication](#) on use of Ozone cleaners), and off-gassing may occur during operation.

These issues can result in serious injury which can be life-threatening, cause permanent impairment, and/or require medical intervention to preclude permanent impairment. To date, Philips Respironics has received several complaints regarding the presence of black debris/particles within the airpath circuit (extending from the device outlet, humidifier, tubing, and mask). Philips also has received reports of headache, upper airway irritation, cough, chest pressure and sinus infection. The potential risks of particulate exposure include: Irritation (skin, eye, and respiratory tract), inflammatory response, headache, asthma, adverse effects to other organs (e.g. kidneys and liver) and toxic carcinogenic affects. The potential risks of chemical exposure due to off-gassing include: headache/dizziness, irritation (eyes, nose, respiratory tract, skin), hypersensitivity, nausea/vomiting, toxic and carcinogenic effects. There have been no reports of death as a result of these issues.

All Devices manufactured before 26 April 2021, All serial numbers	
Continuous Ventilator	Trilogy 100
	Trilogy 200
	Garbin Plus, Aeris, LifeVent
Continuous Ventilator, Minimum Ventilatory Support, Facility Use	A-Series BiPAP Hybrid A30 (not marketed in US)
	A-Series BiPAP V30 Auto
Continuous Ventilator, Non-life Supporting	A-Series BiPAP A40
	A-Series BiPAP A30

Immediate Actions to be taken by You, the User:

1. Do not stop or alter your prescribed therapy until you have talked to your physician. Philips recognizes that alternate ventilator options for therapy may not exist or may be severely limited for patients who require a ventilator for life-sustaining therapy, or in cases where therapy disruption is unacceptable. In these situations, and at the discretion of the treating clinical team, the benefit of continued usage of these ventilator devices may outweigh the risks.
2. If your physician determines that you must continue using this device, **use an inline bacterial filter**. Consult your Instructions for Use for guidance on installation.
3. Register your device(s) on the recall website www.philips.com/src-update
 - a. The website provides you current information on the status of the recall and how to receive permanent corrective action to address the two (2) issues.
 - b. The website also provides you instructions on how to locate your device Serial Number and will guide you through the registration process.
 - c. Call 1-877-907-7508 if you cannot visit the website or do not have internet access.

Permanent Corrective Action to be Taken by the Company:

Philips is deploying a permanent corrective action to address the two (2) issues described in this Recall Notice. As part of the registration process above, you will be provided information on the next steps to implement the permanent solution.

Other Information:

If you need any further information or support concerning this recall/issue, please contact the recall support hotline or visit the website:

1-877-907-7508

www.philips.com/src-update

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or fax.

This notice has been reported to the appropriate Regulatory Agencies.

Philips regrets any inconveniences caused by this problem.

Sincerely,

Rodney Mell
Head of Quality and Regulatory
Philips Respironics - Sleep & Respiratory Care